Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
CONTEXT: First-phase insulin secretion (within 10 min after a sudden rise in plasma glucose) is reduced in type 2 diabetes mellitus (DM2). The incretin mimetic exenatide has glucoregulatory activities in DM2, including glucose-dependent enhancement of insulin secretion. OBJECTIVE: The objective of the study was to determine whether exenatide can restore a more normal pattern of insulin secretion in subjects with DM2. DESIGN: Fasted subjects received iv insulin infusion to reach plasma glucose 4.4-5.6 mmol/liter. Subjects received iv exenatide (DM2) or saline (DM2 and healthy volunteers), followed by iv glucose challenge. PATIENTS: Thirteen evaluable DM2 subjects were included in the study: 11 males, two females; age, 56 +/- 7 yr; body mass index, 31.7 +/- 2.4 kg/m2; hemoglobin A1c, 6.6 +/- 0.7% (mean +/- sd) treated with diet/exercise (n = 1), metformin (n = 10), or acarbose (n = 2). Controls included 12 healthy, weight-matched subjects with normal glucose tolerance: nine males, three females; age, 57 +/- 9 yr; and body mass index, 32.0 +/- 3.0 kg/m2. SETTING: The study was conducted at an academic hospital. MAIN OUTCOME MEASURES: Plasma insulin, plasma C-peptide, insulin secretion rate (derived by deconvolution), and plasma glucagon were the main outcome measures. RESULTS: DM2 subjects administered saline had diminished first-phase insulin secretion, compared with healthy control subjects. Exenatide-treated DM2 subjects had an insulin secretory pattern similar to healthy subjects in both first (0-10 min) and second (10-180 min) phases after glucose challenge, in contrast to saline-treated DM2 subjects. In exenatide-treated DM2 subjects, the most common adverse event was moderate nausea (two of 13 subjects). CONCLUSIONS: Short-term exposure to exenatide can restore the insulin secretory pattern in response to acute rises in glucose concentrations in DM2 patients who, in the absence of exenatide, do not display a first phase of insulin secretion. Loss of first-phase insulin secretion in DM2 patients may be restored by treatment with exenatide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [71]
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 2×
“Diabetes duration (yr) 4 2 NA Diabetes treatment [n (%)] -Glucosidase inhibitors 2 (15) NA Metformin 10 (77) NA Diet/exercise 1 (7) NA”
BackgroundSelf-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Self-citationNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 1×
“Insulin, Cpeptide, and glucagon were determined by specific immunoassays as previously described (28, 29).”
MethodSelf-citationAbnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552 · cited 2×
“with metformin and/or sulfonylureas (20, 21) or different”
BackgroundSelf-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
BRUNZELL, J. D., ROBERTSON, R. P., LERNER, R. L., HAZZARD, W. R., ENSINCK, J. W., BIERMAN, E. L., & PORTE, D. (1976) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-42-2-222 · Cited by 505 · cited 2×
“A PROMINENT FEATURE of type 2 diabetes is a dramatic reduction in first-phase insulin secretion, the insulin normally secreted by pancreatic -cells within 10 min after a sudden rise in plasma glucose concentrations (1).”
BackgroundNielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457 · cited 2×
“Data obtained in animal models also indicate that exenatide and GLP-1 reduce food intake, cause weight loss, and have an insulinsensitizing effect (25, 26).”
BackgroundSelf-citationVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444
Self-citationKolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434 · cited 2×
“with metformin and/or sulfonylureas (20, 21) or different”
BackgroundSelf-citationThe role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus
Pratley, R. E., & Weyer, C. (2001) · Diabetologia · doi:10.1007/s001250100580 · Cited by 419 · cited 1×
“In other studies, without the previous normalization of glycemia through a feedbackregulated insulin infusion, slight elevations in fasting glucose were associated with a reduction in early insulin secretion (4, 36).”
BackgroundCellular composition of the human diabetic pancreas
Rahier, J., Goebbels, R. M., & Henquin, J. C. (1983) · Diabetologia · doi:10.1007/bf00251826 · Cited by 395
Prehepatic Insulin Production in Man: Kinetic Analysis Using Peripheral Connecting Peptide Behavior*
EATON, R. P., ALLEN, R. C., SCHADE, D. S., ERICKSON, K. M., & STANDEFER, J. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-520 · Cited by 363
Polonsky, K. S., Licinio-Paixao, J., Given, B. D., Pugh, W., Rue, P., Galloway, J., Karrison, T., & Frank, B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112308 · Cited by 359 · cited 1×
“(32) and calculated from C-peptide concentrations using the insulin SECretion (ISEC) computer program (3, 33).”
MethodFineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353 · cited 1×
“Plasma exenatide was measured as previously described (30).”
MethodSelf-citationFehmann, H. C. (1992) · Endocrinology · doi:10.1210/en.130.1.159 · Cited by 337 · cited 1×
“cretory granules (45, 46), have contributed to the effects on”
BackgroundMadsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D. R., & on behalf of the NN2211-1310 International Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1335 · Cited by 312
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 285
Self-citationElbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Juhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agersø, H., Veldhuis, J., Pørksen, N., & Schmitz, O. (2002) · Diabetes · doi:10.2337/diabetes.51.2.424 · Cited by 264
Egan, J. M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1282 · Cited by 256 · cited 1×
“regimens of glucose administration (22, 34).”
Degn, K. B., Brock, B., Juhl, C. B., Djurhuus, C. B., Grubert, J., Kim, D., Han, J., Taylor, K., Fineman, M., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2397 · Cited by 254 · cited 1×
“regimens of glucose administration (22, 34).”
Self-citationGedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A. D., Parkes, D. G., & Young, A. A. (2005) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 242 · cited 2×
“Data obtained in animal models also indicate that exenatide and GLP-1 reduce food intake, cause weight loss, and have an insulinsensitizing effect (25, 26).”
BackgroundSelf-citationInsulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
Parkes, D. G., Pittner, R., Jodka, C., Smith, P., & Young, A. (2001) · Metabolism · doi:10.1053/meta.2001.22519 · Cited by 241
Del Prato, S., & Tiengo, A. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.198 · Cited by 238 · cited 2×
“(32) and calculated from C-peptide concentrations using the insulin SECretion (ISEC) computer program (3, 33).”
BackgroundMethodBruce, D. G., Chisholm, D. J., Storlien, L. H., & Kraegen, E. W. (1988) · Diabetes · doi:10.2337/diab.37.6.736 · Cited by 232
Ritzel, R., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 210
Self-citationISEC: a program to calculate insulin secretion
Hovorka, R., Soons, P. A., & Young, M. A. (1996) · Computer Methods and Programs in Biomedicine · doi:10.1016/0169-2607(96)01755-5 · Cited by 177 · cited 1×
“(32) and calculated from C-peptide concentrations using the insulin SECretion (ISEC) computer program (3, 33).”
MethodHolst, J. J. (1982) · Biochemical Journal · doi:10.1042/bj2070381 · Cited by 176
Self-citationHartung, R. (1987) · Toxic Substances and Human Risk · doi:10.1007/978-1-4684-5290-7_3 · Cited by 175
Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 155
Self-citationGutniak, M. K., Linde, B., Holst, J. J., & Efendić, S. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1039 · Cited by 139
Self-citationHosker, J. P., Rudenski, A. S., Burnett, M. A., Matthews, D. R., & Turner, R. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90064-4 · Cited by 125 · cited 2×
“sulfonylureas) have a clinically meaningful influence on first-phase insulin secretion in patients with type 2 diabetes (4, 5).”
BackgroundRachman, J., Gribble, F. M., Barrow, B. A., Levy, J. C., Buchanan, K. D., & Turner, R. C. (1996) · Diabetes · doi:10.2337/diab.45.11.1524 · Cited by 119 · cited 2×
“(9, 37, 38) and different metabolic conditions (5, 39–41).”
BackgroundQuddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111 · cited 6×
“Diabetes duration (yr) 4 2 NA Diabetes treatment [n (%)] -Glucosidase inhibitors 2 (15) NA Metformin 10 (77) NA Diet/exercise 1 (7) NA”
BackgroundMethodInfluentialIncretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes
Nielsen, L. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03460-4 · Cited by 100
Self-citationGlucagon-like peptide 1 (GLP-1) in the treatment of diabetes
Nauck, M. A. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826175 · Cited by 72 · cited 1×
“Nausea 1 (7) 2 (15) 0 (0) Hypoglycemia 2 (14) 2 (15) 0 (0) Fehse et al.”
Self-citationRitzel, R., Schulte, M., Pørksen, N., Nauck, M. S., Holst, J. J., Juhl, C., März, W., Schmitz, O., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.4.776 · Cited by 62 · cited 6×
“00/0 The Journal of Clinical Endocrinology & Metabolism 90(11):5991–5997”
BackgroundSelf-citationAdditive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes
Zander, M., Taskiran, M., Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.720 · Cited by 61
Self-citationByrne, M. M., Gliem, K., Wank, U., Arnold, R., Katschinski, M., Polonsky, K. S., & Goke, B. (1998) · Diabetes · doi:10.2337/diab.47.8.1259 · Cited by 55
SHAPIRO, E. T., CAUTER, E. V., TILLIL, H., GIVEN, B. D., HIRSCH, L., BEEBE, C., RUBENSTEIN, A. H., & POLONSKY, K. S. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-571 · Cited by 54 · cited 1×
“sulfonylureas) have a clinically meaningful influence on first-phase insulin secretion in patients with type 2 diabetes (4, 5).”
BackgroundPørksen, N., Grøfte, T., Nyholm, B., Holst, J. J., Pincus, S. M., Veldhuis, J. D., Schmitz, O., & Butler, P. C. (1998) · Diabetes · doi:10.2337/diab.47.1.45 · Cited by 42
Self-citationEfendić, S., Cerasi, E., Luft, R., & Gladnikoff, G. (1976) · Diabetes · doi:10.2337/diab.25.10.949 · Cited by 32
Holst, J. J. (1983) · Regulatory Peptides · doi:10.1016/0167-0115(83)90766-8 · Cited by 25 · cited 1×
“Insulin, Cpeptide, and glucagon were determined by specific immunoassays as previously described (28, 29).”
MethodSelf-citationFasching, P., Ratheiser, K., Nowotny, P., Uurzemann, S., Parzer, S. B., & Waldhäusl, W. (1994) · Metabolism · doi:10.1016/0026-0495(94)90109-0 · Cited by 24 · cited 1×
“(9, 37, 38) and different metabolic conditions (5, 39–41).”
BackgroundMeier, S., Hücking, K., Ritzel, R. A., Holst, J. J., Schmiegel, W., & Nauck, M. A. (2003) · Hormone and Metabolic Research · doi:10.1055/s-2003-42658 · Cited by 18 · cited 2×
“subjects (6, 7), subjects with impaired glucose tolerance (8),”
BackgroundSelf-citationRegulation of Islet Hormone Gene Expression by Incretin Hormones
Fehmann, H. C., Gherzi, R., & Göke, B. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211395 · Cited by 14 · cited 1×
“cretory granules (45, 46), have contributed to the effects on”
BackgroundIslet Cell-populations in Obese Subjects and Type-2 (non-insulin-dependent) Diabetic-patients
Rahier, J., Ibrahim, M., & Channaoui, K. (1989) · Diabetologia · Cited by 4
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“glucose in patients with T2DM, hence improving the ability of cells to response to rapid glycemic changes (Fehse et al., 2005).”
BackgroundPancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men
Rorsman, P., & Ashcroft, F. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00008.2017 · Cited by 793
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
“This effect is consistent with the ability of exenatide to improve -cell function acutely (83).”
Result
Metadata
- Authors
- Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Eli Lilly (United States) (US)
- University of Copenhagen (DK)
- Corresponding author
- Nauck, Michael A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-11
- Volume
- 90
- Issue
- 11
- Pages
- 5991-5997
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2039296612
- Cited by
- 297
- References
- 55
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 24 · 2014: 22 · 2013: 21 · 2012: 9
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, type 2 diabetes, first-phase insulin secretion, second-phase insulin secretion, incretin mimetics, glucose-dependent insulin secretion, insulin secretion rate, C-peptide, glucagon, insulin resistance, metformin, acarbose, glucoregulation, GLP-1 receptor
- MeSH terms
- Exenatide, Insulin Secretion, Adult, Diabetes Mellitus, Type 2, Female, Glucose, Humans, Insulin, Male, Middle Aged, Peptides, Venoms, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.